laekna news - Search News

Laekna, obesity and Eli Lilly

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.

Business Insider · 2d

Eli Lilly and China-based biotech Laekna team on obesity drug

Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its

Seeking Alpha · 3d

Eli Lilly in pact with Chinese biotech for novel weight loss therapy

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.

The Pharma Letter · 2d

Lilly and Laekna team up on novel obesity drugs

Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle regeneration. The collaboration, funded by Lilly, aims to enhance fat reduction and muscle preservation,

Business Wire3d

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

2d

Laekna, Inc. Announces Share Placement to Raise HK$230 Million

Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

阿思達克財經網2d

LAEKNA-B Last Slumps 7%+ after Announcing Shr Placing on 48% Rally Ytd

LAEKNA-B (02105.HK) announced a share placing immediately after a 48% share surge yesterday (20th). Today (21st), it opened ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results